GR 144053 trihydrochloride
Cat. No. 1263
Chemical Name: 4-[4-[4-(Aminoiminomethyl)phenyl]-1
Biological ActivityA potent and selective platelet fibrinogen receptor glycoprotein IIb/IIIa (GpIIb/IIIa) antagonist (IC50 = 37 nM). Orally active and highly effective at inhibiting thrombus formation in vivo.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Matsuno et al (1999) Comparative antiplatelet effects of aspirin, vapiprost and GR 144053, a GPIIb/IIIa antagonist with special reference to the role of platelet microaggregates. Br.J.Pharmacol. 127 1129. PMID: 10455258.
Matsuno et al (1997) GR 144053, a fibrinogen receptor antagonist, enhances the suppression of neointima formation by losartan, an angiotensin II receptor antagonist, in the injured carotid artery of hamster. Br.J.Pharmacol. 122 1099. PMID: 9480031.
Eldred et al (1994) Orally active non-peptide fibrinogen receptor (GpIIb/IIIa) antagonists: identification of 4-[4-[4-(aminoiminomethyl)phenyl]-1-piperazinyl]-1-piperidineacetic acid as a long-acting, broad spectrum antithrombotic agent. J.Med.Chem. 37 3882. PMID: 7966149.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses GR 144053 trihydrochloride from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: GR 144053 trihydrochloride, supplier, Glycoprotein, IIb/IIIa, αIIbβ3, alphaIIbβ3, beta3, antagonists, Antithrombotic, receptor, Adhesion, Molecules, Integrin, Receptors, GR144053, trihydrochloride, Tocris Bioscience, Integrin Receptor Inhibitor products
Find multiple products by catalog number
New Products in this Area
α5β1 integrin receptor antagonistFSL 1
TLR2/6 agonist (also a putative TLR10 ligand)Cilengitide
Potent and selective inhibitor of integrins αvβ3 and αvβ5SM 324405
Potent TLR7 agonist
One Day Symposium
March 1, 2017
Amsterdam, The Netherlands